Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.
|Videos|October 27, 2020
Educated Patient® Leukemia and Lymphoma Summit: October 27, 2020
Author(s)CURE Media Group
View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.
Advertisement
View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.
Advertisement
Related to this article
Dr. Matteo Lambertini explains how Lynkuet reduced hot flashes in people on endocrine therapy for breast cancer, no matter when their treatment began.
Dr. Sara Hurvitz explains why giving Enhertu before surgery didn't change care for HER2-low, HR-positive early breast cancer, and what patients should know.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
4
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
5